• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pediatric blood & cancer >Improved Treatment Results of Children With B-Cell Non-Hodgkin Lymphoma: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study
【24h】

Improved Treatment Results of Children With B-Cell Non-Hodgkin Lymphoma: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study

机译：B细胞非霍奇金淋巴瘤患儿的治疗效果得到改善：日本小儿白血病/淋巴瘤研究组B-NHL03研究的报告

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Involved field radiation therapy (IFRT) is integral in curative therapy for Hodgkin lymphoma (HL), although primarily used in patients with intermediate/high-risk HL. We present failure patterns and clinical outcomes in a cohort of pediatric and young adult patients with HL treated with IFRT at the Johns Hopkins Hospital. Procedure Patients <= 40 years old with intermediate/high-risk HL who received chemotherapy and IFRT from 1997 to 2012 were included in this retrospective analysis. Patients were evaluated for failure patterns, overall survival (OS), and event-free survival (EFS) using Kaplan-Meier curves, descriptive statistics, and Cox proportional hazard regressions. Results We reviewed 74 patients (45 pediatric and 29 young adult) with a median follow-up of 4.4 years. The mean age at diagnosis was 21.4 years. Patients received a median of 29.75 Gy of IFRT (range 15-39.6 Gy). The majority of pediatric patients received ABVE-PC chemotherapy (n = 25) and <30 Gy of radiation (n = 33) while most young adults received ABVD chemotherapy (n = 24) and >= 30 Gy (n = 25). Estimated 5-year OS and EFS were 96% and 81%, respectively. Thirteen patients had recurrence; eight were pediatric. Distant relapse alone comprised 83% of failures in patients receiving >= 30 Gy. Of the seven patients who received <30 Gy and had recurrence, six had local failure as a component of their recurrence. Caucasian race (P = 0.02) and nodular sclerosing histology (P = 0.01) predicted for increased EFS. Late effects were minimal and all deaths (n = 4) were from HL. Conclusions In this series, pediatric and young adult patients were treated with differing chemoradiation and had distinct recurrence patterns. Pediatr Blood Cancer 2014;61:1210-1214. (c) 2014 Wiley Periodicals, Inc.
机译：背景技术介入放射治疗（IFRT）在霍奇金淋巴瘤（HL）的治疗中必不可少，尽管它主要用于中/高危HL患者。我们在约翰·霍普金斯医院（Johns Hopkins Hospital）的一组接受IFRT治疗的HL患儿和年轻成年HL患者中，介绍了其失败模式和临床结果。程序本回顾性分析纳入了1997年至2012年接受化疗和IFRT且≤40岁的中/高危HL患者。使用Kaplan-Meier曲线，描述性统计数据和Cox比例风险回归对患者的失败模式，总生存期（OS）和无事件生存期（EFS）进行评估。结果我们回顾了74位患者（45位儿科患者和29位年轻成年人），中位随访时间为4.4年。诊断时的平均年龄为21.4岁。患者接受IFRT的中位值为29.75 Gy（范围为15-39.6 Gy）。大多数儿科患者接受ABVE-PC化疗（n = 25）和<30 Gy放射线（n = 33），而大多数年轻人接受ABVD化疗（n = 24）和> = 30 Gy（n = 25）。估计5年OS和EFS分别为96％和81％。 13例患者复发;八个是小儿科。 ≥30 Gy的患者中，仅远处复发就占失败的83％。在接受＜30 Gy且复发的7例患者中，有6例具有局部衰竭作为其复发的一部分。高加索人种（P = 0.02）和结节性硬化组织学（P = 0.01）预测EFS升高。后期影响极小，所有死亡（n = 4）均来自HL。结论在该系列中，小儿和成年青年患者接受了不同的化学放射治疗，并具有不同的复发模式。小儿血液癌2014; 61：1210-1214。 （c）2014年威利期刊有限公司

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号